 Virios Therapeutics Inc NASDAQ: VIRI has announced that data from its Phase 2a PRID-201 trial demonstrated that IMC-1 was better tolerated than placebo in patients with fibromyalgia. The disease is characterized by widespread musculoskeletal pain accompanied by fatigue, sleep, memory, and mood issues. 